Korro Bio's Initial Trial Results Disappoint; Shares Reach Record Low
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 13 2025
0mins
Should l Buy NVO?
Source: Benzinga
Stock Performance: Korro Bio, Inc. (NASDAQ: KRRO) experienced a significant decline in stock price, dropping 80% to $6.27, with a trading volume of 6.68 million shares compared to the average of 1.42 million.
Clinical Trial Update: The company reported that its KRRO-110 treatment for alpha-1 antitrypsin deficiency (AATD) produced functional M-AAT protein in patients, but did not meet the expected protein levels based on preclinical data.
Strategic Restructuring: Korro is implementing a workforce reduction of approximately 34% to focus on advancing its GalNAc-conjugated programs and extending its cash runway into the second half of 2027.
Analyst Downgrade: William Blair downgraded Korro's stock from Outperform to Market Perform, citing concerns over the competitiveness of KRRO-110 and the pause in collaboration with Novo Nordisk.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVO
Wall Street analysts forecast NVO stock price to rise
8 Analyst Rating
4 Buy
3 Hold
1 Sell
Moderate Buy
Current: 35.290
Low
42.00
Averages
54.67
High
70.00
Current: 35.290
Low
42.00
Averages
54.67
High
70.00
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Novo Nordisk Launches Wegovy Subscription Program for Weight Loss Therapy
- Innovative Subscription Model: Novo Nordisk has launched the first-ever Wegovy (semaglutide) subscription program, allowing patients to choose 3-, 6-, or 12-month subscriptions through telehealth platforms like LifeMD and Hims & Hers, aimed at reducing treatment barriers and enhancing drug accessibility.
- Cost Savings Advantage: According to the company, patients on a 12-month subscription can save up to $600 annually on Wegovy pills and $1,200 on Wegovy injections, significantly alleviating financial burdens and promoting long-term treatment adherence.
- Market Expansion Strategy: Initially available through platforms like Ro, WeightWatchers, and LifeMD, the program is set to expand to Hims & Hers and Sesame, reflecting Novo Nordisk's strategic positioning and intent to penetrate the digital health market.
- Patient Support Commitment: Ed Cinca, Senior Vice President at Novo, stated that the subscription program offers patients a simple, affordable, and consistent FDA-approved treatment option, aimed at enhancing patient experience and satisfaction, thereby solidifying the company's leadership in the weight loss medication market.
See More
Market Rallies on Signs of Iran Conflict De-escalation
- Market Rally: The S&P 500 surged over 2% on Tuesday amid signs of potential de-escalation in the Iran conflict, reflecting investor optimism, although caution is still warranted regarding this signal.
- Eli Lilly Acquisition: Eli Lilly announced its acquisition of Centessa Pharmaceuticals for up to $7.8 billion, focusing on new treatments for excessive daytime sleepiness, with peak sales for its key asset cleminorexton projected to exceed $3 billion, further solidifying Lilly's position in neuroscience.
- Novo Nordisk Competition: Novo Nordisk launched a subscription program to lower prices on Wegovy, aiming to reclaim market share from Eli Lilly, which leads in the GLP-1 category, highlighting the need for continuous innovation to maintain competitive advantage.
- Analyst Ratings: Truist initiated coverage of Corning with a hold rating and a $125 price target, expressing optimism about its optical business growth while raising concerns over current valuations, indicating a cautious market outlook on Corning's future growth potential.
See More
Snap Shares Surge on Activist Investor Proposal
- Snap Share Surge: Shares of social media platform Snap surged 12% after activist investor Irenic disclosed a 2.5% stake and proposed shutting down its augmented reality Specs business to boost share prices, indicating strong market confidence in its strategic direction.
- FactSet Earnings Beat: FactSet's adjusted earnings for Q2 came in at $4.46 per share, exceeding the consensus estimate of $4.38, while the company raised its full-year guidance to an expected adjusted earnings range of $17.25 to $17.75 per share, reflecting robust market performance and growth potential.
- Symbotic Strategic Agreement: Robotics company Symbotic's stock jumped nearly 5% following a strategic agreement to provide warehouse automation capabilities at Associated Wholesale Grocers' Gulf Coast Division Support Center in Louisiana, highlighting its expansion in logistics automation and growing market demand.
- Apellis Pharmaceuticals Stock Doubles: Shares of Apellis Pharmaceuticals soared 135% after Biogen announced it would acquire the company for $5.6 billion in cash, enhancing Biogen's portfolio in immunology and rare diseases, showcasing strong market approval for the deal.
See More
Novo Nordisk Cuts GLP-1 Drug Prices in India Amid Competition
- Price Reduction: Novo Nordisk has lowered the prices of Ozempic and Wegovy in India to ₹1,415 ($15.04) for the lowest doses, down from ₹2,200 and ₹2,712, representing reductions of 23.8% and 27% respectively, aimed at countering competition from local generics.
- Increased Market Competition: Following the expiration of a key patent on March 20, at least six local pharmaceutical companies have launched off-patent versions of semaglutide, forcing Novo Nordisk to adopt a pricing strategy to maintain its market share.
- Profit Forecast Downgrade: In February, Novo Nordisk projected a potential 13% decline in profits for 2023 due to patent expirations, indicating ongoing pressure from generics that could impact its profitability.
- Response to Patient Feedback: Vikrant Shrotriya, managing director of Novo Nordisk India, stated that the company is acting on feedback from patients and doctors, demonstrating its sensitivity and adaptability to market demands.
See More
Stock Index Futures Rise as Investors Eye Four Key Companies
- Nike Earnings Focus: Nike (NKE) is set to report its fiscal third-quarter results after the market closes, with analysts expecting revenue of $11.2 billion and earnings per share of $0.28, down from last year's $0.54, prompting investors to closely monitor demand trends in China and margin outlook amid new challenges.
- Novo Nordisk Subscription Program: Novo Nordisk (NVO) slipped 0.14% in premarket trading after announcing a first-of-its-kind subscription program for its weight loss therapy Wegovy, allowing cash-paying patients to choose 3-, 6-, or 12-month subscriptions starting March 31, with longer terms offering lower monthly prices.
- Marvell Technology Surge: Marvell Technology (MRVL) jumped over 10% in premarket trading following Nvidia's announcement of a $2 billion investment and a strategic partnership to connect Marvell to Nvidia's AI factory and AI-RAN ecosystem, enhancing its market position in AI technologies.
- Eli Lilly Acquires Centessa: Eli Lilly (LLY) gained 0.86% before the opening bell after announcing a definitive agreement to acquire Centessa Pharmaceuticals for $38.00 per share in cash, which will bolster Lilly's portfolio in treating excessive daytime sleepiness and other neurological conditions.
See More
Novo Nordisk Launches Discounted Subscription Plan for Wegovy
- Discounted Subscription Plan: Novo Nordisk has introduced a discounted subscription plan for U.S. patients paying out of pocket for its obesity drug Wegovy, allowing savings of up to $600 annually on pills and $1,200 on injections, aimed at enhancing competitiveness against Eli Lilly.
- Flexible Subscription Options: Eligible patients can choose from three-, six-, or twelve-month subscriptions through telehealth platforms like Ro, WeightWatchers, and LifeMD, with larger discounts for longer commitments, thereby improving medication adherence among patients.
- Price Comparison: Monthly prices for Wegovy injections range from $329 for a three-month plan to $249 for a year-long subscription, compared to the usual $349, indicating a significant price advantage, while the pill version is priced between $249 and $289.
- Market Reaction: Despite the launch of the new plan, Novo Nordisk's shares edged down 0.3% in pre-market trading on Tuesday, reflecting a cautious market sentiment regarding the strategy's potential impact on the company's future market performance.
See More
Novo Nordisk Launches Wegovy Subscription Program for Weight Loss Therapy
- Innovative Subscription Model: Novo Nordisk has launched the first-ever Wegovy (semaglutide) subscription program, allowing patients to choose 3-, 6-, or 12-month subscriptions through telehealth platforms like LifeMD and Hims & Hers, aimed at reducing treatment barriers and enhancing drug accessibility.
- Cost Savings Advantage: According to the company, patients on a 12-month subscription can save up to $600 annually on Wegovy pills and $1,200 on Wegovy injections, significantly alleviating financial burdens and promoting long-term treatment adherence.
- Market Expansion Strategy: Initially available through platforms like Ro, WeightWatchers, and LifeMD, the program is set to expand to Hims & Hers and Sesame, reflecting Novo Nordisk's strategic positioning and intent to penetrate the digital health market.
- Patient Support Commitment: Ed Cinca, Senior Vice President at Novo, stated that the subscription program offers patients a simple, affordable, and consistent FDA-approved treatment option, aimed at enhancing patient experience and satisfaction, thereby solidifying the company's leadership in the weight loss medication market.
See More
Market Rallies on Signs of Iran Conflict De-escalation
- Market Rally: The S&P 500 surged over 2% on Tuesday amid signs of potential de-escalation in the Iran conflict, reflecting investor optimism, although caution is still warranted regarding this signal.
- Eli Lilly Acquisition: Eli Lilly announced its acquisition of Centessa Pharmaceuticals for up to $7.8 billion, focusing on new treatments for excessive daytime sleepiness, with peak sales for its key asset cleminorexton projected to exceed $3 billion, further solidifying Lilly's position in neuroscience.
- Novo Nordisk Competition: Novo Nordisk launched a subscription program to lower prices on Wegovy, aiming to reclaim market share from Eli Lilly, which leads in the GLP-1 category, highlighting the need for continuous innovation to maintain competitive advantage.
- Analyst Ratings: Truist initiated coverage of Corning with a hold rating and a $125 price target, expressing optimism about its optical business growth while raising concerns over current valuations, indicating a cautious market outlook on Corning's future growth potential.
See More
Snap Shares Surge on Activist Investor Proposal
- Snap Share Surge: Shares of social media platform Snap surged 12% after activist investor Irenic disclosed a 2.5% stake and proposed shutting down its augmented reality Specs business to boost share prices, indicating strong market confidence in its strategic direction.
- FactSet Earnings Beat: FactSet's adjusted earnings for Q2 came in at $4.46 per share, exceeding the consensus estimate of $4.38, while the company raised its full-year guidance to an expected adjusted earnings range of $17.25 to $17.75 per share, reflecting robust market performance and growth potential.
- Symbotic Strategic Agreement: Robotics company Symbotic's stock jumped nearly 5% following a strategic agreement to provide warehouse automation capabilities at Associated Wholesale Grocers' Gulf Coast Division Support Center in Louisiana, highlighting its expansion in logistics automation and growing market demand.
- Apellis Pharmaceuticals Stock Doubles: Shares of Apellis Pharmaceuticals soared 135% after Biogen announced it would acquire the company for $5.6 billion in cash, enhancing Biogen's portfolio in immunology and rare diseases, showcasing strong market approval for the deal.
See More
Novo Nordisk Cuts GLP-1 Drug Prices in India Amid Competition
- Price Reduction: Novo Nordisk has lowered the prices of Ozempic and Wegovy in India to ₹1,415 ($15.04) for the lowest doses, down from ₹2,200 and ₹2,712, representing reductions of 23.8% and 27% respectively, aimed at countering competition from local generics.
- Increased Market Competition: Following the expiration of a key patent on March 20, at least six local pharmaceutical companies have launched off-patent versions of semaglutide, forcing Novo Nordisk to adopt a pricing strategy to maintain its market share.
- Profit Forecast Downgrade: In February, Novo Nordisk projected a potential 13% decline in profits for 2023 due to patent expirations, indicating ongoing pressure from generics that could impact its profitability.
- Response to Patient Feedback: Vikrant Shrotriya, managing director of Novo Nordisk India, stated that the company is acting on feedback from patients and doctors, demonstrating its sensitivity and adaptability to market demands.
See More
Stock Index Futures Rise as Investors Eye Four Key Companies
- Nike Earnings Focus: Nike (NKE) is set to report its fiscal third-quarter results after the market closes, with analysts expecting revenue of $11.2 billion and earnings per share of $0.28, down from last year's $0.54, prompting investors to closely monitor demand trends in China and margin outlook amid new challenges.
- Novo Nordisk Subscription Program: Novo Nordisk (NVO) slipped 0.14% in premarket trading after announcing a first-of-its-kind subscription program for its weight loss therapy Wegovy, allowing cash-paying patients to choose 3-, 6-, or 12-month subscriptions starting March 31, with longer terms offering lower monthly prices.
- Marvell Technology Surge: Marvell Technology (MRVL) jumped over 10% in premarket trading following Nvidia's announcement of a $2 billion investment and a strategic partnership to connect Marvell to Nvidia's AI factory and AI-RAN ecosystem, enhancing its market position in AI technologies.
- Eli Lilly Acquires Centessa: Eli Lilly (LLY) gained 0.86% before the opening bell after announcing a definitive agreement to acquire Centessa Pharmaceuticals for $38.00 per share in cash, which will bolster Lilly's portfolio in treating excessive daytime sleepiness and other neurological conditions.
See More
Novo Nordisk Launches Discounted Subscription Plan for Wegovy
- Discounted Subscription Plan: Novo Nordisk has introduced a discounted subscription plan for U.S. patients paying out of pocket for its obesity drug Wegovy, allowing savings of up to $600 annually on pills and $1,200 on injections, aimed at enhancing competitiveness against Eli Lilly.
- Flexible Subscription Options: Eligible patients can choose from three-, six-, or twelve-month subscriptions through telehealth platforms like Ro, WeightWatchers, and LifeMD, with larger discounts for longer commitments, thereby improving medication adherence among patients.
- Price Comparison: Monthly prices for Wegovy injections range from $329 for a three-month plan to $249 for a year-long subscription, compared to the usual $349, indicating a significant price advantage, while the pill version is priced between $249 and $289.
- Market Reaction: Despite the launch of the new plan, Novo Nordisk's shares edged down 0.3% in pre-market trading on Tuesday, reflecting a cautious market sentiment regarding the strategy's potential impact on the company's future market performance.
See More
